Short-Term DAPT After Implantation of Zotarolimus-Eluting Stents

Three months of therapy is a real option in patients with stable coronary artery disease.

Current guidelines recommend prolonged dual antiplatelet therapy (DAPT) for patients undergoing implantation of drug-eluting stents (DES). However, the optimal duration of DAPT for specific types of DES remains unclear.

To assess the clinical outcomes of 3 months (short term) versus 12 months (long term) of DAPT following percutaneous coronary intervention (PCI) with zotarolimus-eluting stents, investigators conducted a manufacturer-sponsored, open-label, active-controlled, noninferiority trial. They randomized 3119 patients in Brazil undergoing PCI with zotarolimus-eluting stents to receive short-term or long-term therapy with aspirin (100–200 mg daily) and clopidogrel (75 mg daily). Two thirds of patients had coronary artery disease, and o…

Reviewing Author

Beat J. Meyer, MD

Disclosures

Leadership positions in professional societiesBern Heart Foundation (President); International Academy of Medicine, Bern, Switzerland (Director)

Beat J. Meyer, MD

Disclosures

Leadership positions in professional societiesBern Heart Foundation (President); International Academy of Medicine, Bern, Switzerland (Director)

Short-Term DAPT After Implantation of Zotarolimus-Eluting Stents

Topics

Reviewing Author